Ogalvibart/Crexavibart

N/A

Report date: 2025/12/22 11:25:54

Base Information

Drug NameOgalvibart/Crexavibart
Drug Alias NameBMS-986414 + BMS-986413BMS-986414/C 144LSC 144LS/BMS-986414C 144LS/IM051C 144LS/ogalvibart +[8] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionCoronavirus spike glycoprotein inhibitors
TargetsCoronavirus spike glycoprotein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Coronavirus Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesPuerto Rico +[9] 
CombinationsYes OgalvibartCrexavibart
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesThe Rockefeller UniversityBristol Myers Squibb Srlcompany
China Registration ClassN/A

Develop Information

Active CompaniesBristol Myers Squibb SrlcompanyNational Institute Of Allergy And Infectious Diseases (Niaid)The Rockefeller University
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Coronavirus Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A